drugset / Trial / NCT06919679
Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Participants receive chemotherapy with BrECADD in standard doses and cycle length. After the first two cycles, a restaging is performed by contrast-enhanced computed tomography (ceCT) and PET (PET/CT) in order to guide response-adapted continuation of therapy consisting of 4 or only 2 additional cycles of BrECADD in case of a PET-positive or -negative staging result, respectively. A second restaging will be performed after completion of chemotherapy. In patients with PET-positive residual disease, local irradiation followed by another restaging is recommended. ART should be continued during chemotherapy.
Timeline
- Start
- 2025-08
- Primary completion
- 2028-01
- Completion
- 2030-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brentuximab Vedotin | Monoclonal antibody | — | — |
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Dacarbacine | Unknown | — | — |
| Subject | Dexamethasone | Small molecule | — | — |
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Etoposide | Small molecule | — | — |